Netherlands
# |
Name |
EBITDA |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 688.55 M
|
Dec. 31, 2023 | USD 45.57 | -0.94% |
|
Netherlands |
|
2 |
USD 218.54 M
|
Dec. 31, 2023 | USD 22.92 | 2.26% |
|
Netherlands |
|
3 |
USD 9.88 M
|
Dec. 31, 2023 | USD 9.93 | 5.98% |
|
Netherlands |
|
4 |
USD -26.60 M
|
Dec. 31, 2023 | USD 2.26 | -0.44% |
|
Netherlands |
|
5 |
USD -40.42 M
|
Dec. 31, 2023 | USD 0.98 | -1.01% |
|
Netherlands |
|
6 |
USD -106.90 M
|
Dec. 31, 2023 | USD 16.00 | -2.50% |
|
Netherlands |
|
7 |
USD -154.01 M
|
Dec. 31, 2023 | USD 39.01 | -3.56% |
|
Netherlands |
|
8 |
USD -176.86 M
|
Dec. 31, 2023 | USD 23.67 | -3.70% |
|
Netherlands |
|
9 |
USD -192.28 M
|
Dec. 31, 2023 | USD 673.61 | 1.66% |
|
Netherlands |
|
10 |
USD -253.10 M
|
Dec. 31, 2023 | USD 13.23 | -4.06% |
|
Netherlands |
The Biotechnology company in Netherlands with the highest EBITDA is Qiagen N.V. (NYSE: QGEN) at USD 688.55 M.
The Biotechnology company in Netherlands with the lowest EBITDA is uniQure N.V. (NasdaqGS: QURE) at USD -253.10 M.
The top 10 Biotechnology companies in Netherlands by EBITDA are Qiagen N.V., Corbion N.V., Pharming Group N.V., ProQR Therapeutics N.V., LAVA Therapeutics N.V., Pharvaris N.V., Merus N.V., NewAmsterdam Pharma Company N.V., argenx SE and uniQure N.V..
The bottom 10 Biotechnology companies in Netherlands by EBITDA are uniQure N.V., argenx SE, NewAmsterdam Pharma Company N.V., Merus N.V., Pharvaris N.V., LAVA Therapeutics N.V., ProQR Therapeutics N.V., Pharming Group N.V., Corbion N.V. and Qiagen N.V..